The incidence of acute myocardial infarction (AMI) has fallen by 23% over the past 20 years in the Hunter New England Local Health district (HNELHD), 1 which covers an area of over 130 000 km 2 and has a single 24-hour primary percutaneous intervention (PCI) centre serving a population of over 900 000. This geographical area is comparable to England in size, which has 69 primary PCI centres. Travel time to our PCI centre can be up to five hours. Therefore, in patients whom the estimated time to PCI centre is greater than 60 min, thrombolysis is preferred. The falling incidence of AMI in Australia seems to be primarily driven by a 30% decline in ST-elevation myocardial infarction (STEMI).
Despite the falling incidence and reduced mortality following AMI, we have shown an increase in total heart failure (HF) hospitalisations in the HNELHD. 4 While population growth and ageing partly explain these findings, controversy exists as to whether the improved survival postAMI is contributing to the HF epidemic.
In the context of these temporal trends of AMI and HF, the rate of HF admission in patients who have suffered STEMI has not been well defined in a contemporary population. We sought to evaluate this relationship and define characteristics that might predict patients at high risk of being readmitted with HF following STEMI.
Participants, methods and results
All patients admitted in the HNELHD with AMI were identified from the Hunter Cardiovascular and Stroke Outcomes Unit. They were included if they had International Statistical Classification of Diseases and Related Health Problems (ICD) 10 code of I21 or an ICD 9 code of 410 on discharge from any HNELHD hospital from the period 1 January 2005 to 31 December 2013. An individual patient could only be included once per calendar year and patients with a non-STEMI were excluded by reviewing the patient's medical records.
Similarly, all HF admissions within the HNELHD were identified for the period 1 January 2005 to 31 December 2014. Patients were included if they had an ICD 10 code I-50 on discharge as the primary diagnosis or one of the first three secondary diagnoses. The two databases were matched based on three identifiers: date of birth, sex and a unique medical record number. In order to define the true incidence of re-admission with HF postSTEMI, patients who died during their index admission were excluded from the analysis.
A total of 2375 STEMI patients was identified from 1 January 2005 to 31 December 2013. Of these, 322 (13.6%) went on to have a readmission with HF over a median follow-up period of 4.6 years. We used t-test to compare continuous variables and v 2 to compare categorical variables.
Compared to STEMI patients who did not have a HF admission, those STEMI patients who did have HF admission were older (mean age 77 years versus 64 years, P < 0.01), more likely to be female (43% versus 29%, P < 0.001), were less likely to have received PCI during the index STEMI admission (34% versus 54%, P < 0.01) and were more likely to have multiple co-morbidities, including diabetes (P < 0.01), hypertension (P < 0.01) and atrial fibrillation (P < 0.01). Age, atrial fibrillation and diabetes were independent predictors of developing HF on multivariable analysis. These findings are concordant with previous studies. 5 Mortality was higher in patients readmitted with HF (20% versus 6% at 1 year, P < 0.01) and 3-and 5-year rates of 36% versus 10% and 47% versus 14%, respectively (P < 0.01) from the index admission with STEMI.
To identify temporal trends, we divided the cohort into two eras, from 2005 to 2008 and from 2009 to 2013; one-year mortality was relatively static at 8% versus 7% (P = 0.12). The overall incidence of HF readmission was significantly reduced in the latter era, with one-year readmission rates of 7% versus 11% (P = 0.004) and 3-and 5-year rates of 10% versus 13% (P = 0.016) and 11% versus 14% (P = 0.025), respectively. The reduced incidence of HF readmission might be related to the increased use of PCI (66% versus 38%, P < 0.01). While the reduction in mortality from early to later era was maintained in the patients without HF readmission, there was no reduction in mortality seen in those with HF readmission, as shown in Figure 1 . Women had a significantly worse mortality (9% versus 7% at one year, P = 0.017) and HF readmission rate (12% versus 8% at one year, P < 0.01).
One important limitation of the present analysis to consider is that the ICD code I-50 does not discriminate between HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction. Although ischaemic heart disease is a risk factor for HFpEF, 6 age, atrial fibrillation and hypertension are also known to be risk factors for developing HFpEF.
The lack of effective treatments for HFpEF might explain why mortality has not fallen despite the reduced incidence of HF readmissions.
Comment
We have shown that readmission rates with HF are decreasing following STEMI; however, readmission is associated with a significantly increased mortality. Increasing age and co-morbidities, including atrial fibrillation and diabetes, were all independent predictors of readmission with HF. Despite improvements in STEMI mortality and reduced incidence of HF readmission postSTEMI, those who develop HF remain at very high risk for death.
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